Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Abstract

Background: A novel chewable oral tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™) has recently been developed to provide persistent protection against flea and tick infections for a month, treatment of hookworm and roundworm infections and prevention of heartworm and lungworm disease in dogs. Two field studies were conducted to evaluate the safety and efficacy of Simparica Trio ™ against natural flea and tick infestations on dogs in Europe. Methods: Dogs with natural flea or tick infestations were allocated randomly to treatment on Day 0 with either Simparica Trio ™ tablets (flea study: n = 297; tick study: n = 189) to provide 1.2-2.4 mg/kg sarolaner, 24-48 µg/kg moxidectin and 5-10 mg/kg pyrantel (as pamoate salt) or with NexGard ® Spectra (afoxolaner + milbemycin oxime) according to the label instructions (flea study: n = 164; tick study: n = 91). Efficacy was calculated based on the mean percent reduction in live parasite counts compared to the respective pre-treatment counts on Days 14 and 30 in the flea study and on Days 7, 14, 21 and 30 in the tick study. To count the fleas, the dog's entire coat was systematically combed using an extra fine-tooth flea comb until all fleas were removed. For the tick counts, the dog's entire coat was searched manually. Resolution of the clinical signs of flea allergy dermatitis (FAD) was assessed in flea allergic dogs in the flea study. Palatability was assessed in both studies. Results: Simparica Trio ™ was well tolerated in both studies. Efficacy against fleas was ≥ 97.9% in the Simparica Trio ™ group and ≥ 96.1% in the NexGard ® Spectra group. Efficacy against ticks was ≥ 94.8% in the Simparica Trio ™ group and ≥ 94.4% in the NexGard ® Spectra group. Clinical signs of flea allergy dermatitis improved following treatment with Simparica Trio ™. Simparica Trio ™ tablets were voluntarily and fully consumed on ≥ 78% of the 485 occasions they were offered. Conclusions: A single oral dose of Simparica Trio ™ was safe and highly efficacious against naturally occurring flea and tick infestations for 1 month on dogs. Clinical signs of FAD improved following treatment. Simparica Trio ™ was voluntarily and readily consumed by most dogs.

Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

“…In addition to internal parasites, dogs are also at risk for infestation with fleas and ticks, which can have deleterious effects on their hosts including the transmission of disease agents to both dogs and humans; therefore, regular treatment of dogs at risk for these parasites is recommended [22][23][24][25]. The efficacy of Simparica Trio ™ against flea and tick infestations both under field and laboratory conditions has been demonstrated [26][27][28][29][30].…”

Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

“…The preventative efficacy of Simparica Trio ® for angiostrongylosis has recently been confirmed in placebo-controlled, randomized, masked laboratory studies where dogs were experimentally infected with A. vasorum [37]. Simparica Trio ® , besides preventing angiostrongylosis, also provides effective treatment of flea and/or tick infestations due to the inclusion of sarolaner [38,39] and, due to pyrantel and moxidectin inclusion, efficacy against four gastrointestinal nematode species [40]. Additionally, the 24-48 µg/kg moxidectin dose in the combination is effective in the prevention of heartworm disease caused by Dirofilaria immitis [41].…”

Recent Advancements in the Control of Cat Fleas

“…In a laboratory study, the number of fleas on dogs orally dosed with afoxolaner was reduced by 100% for at least 22 days [ 48 ]. An oral dose of afoxolaner + milbemycin oxime to naturally infested dogs provided ≥96.1% reductions of fleas at day 30 [ 49 ]. In a field trial with 37 naturally infested dogs in Tampa FL, USA, dogs were provided an oral dose of afoxolaner.…”

“…Both treatments provided >90% anti-attachment of Rhipicephalus sanguineus for at least 14 days [ 48 ]. An oral dose of afoxolaner + milbemycin oxime provided ≥94.4% reductions of ticks on naturally infested dogs at day 30 [ 49 ].…”